OneSource Specialty Pharma Reports Strong Q1 FY27 Results; Revenue Up 37% YoY

OneSource Specialty Pharma Reports Strong Q1 FY27 Results; Revenue Up 37% YoY​

OneSource Specialty Pharma Limited announced consolidated financial results for the quarter ending June 30, 2026, highlighting robust growth across its specialty CDMO business. The company reported a significant increase in revenue and EBITDA, driven by various commercial milestones and operational leverage.

The company’s performance during Q1 FY27 demonstrated strong momentum. Revenue reached ₹4,490m, marking a 37% year-on-year (YoY) rise and a 5% quarter-on-quarter (QoQ) increase. EBITDA stood at ₹1,233m, representing a 39% YoY increase and a 34% QoQ jump. This operational efficiency led to the company achieving an EBITDA margin of 27.5%, up from 21.5% in Q4 FY26. Adjusted PAT was reported at ₹637m, resulting in an adjusted EPS of ₹5.6.

Financial performance metrics for OneSource Specialty Pharma Limited are detailed below:


Neeraj Sharma, CEO & MD of OneSource Specialty Pharma Limited, stated that the company began FY27 on a strong note, driven by the commercialization of semaglutide in Canada and India. He highlighted further momentum in the biologics business due to the addition of another leading global biosimilar customer, which reinforces the strength of the integrated CDMO capabilities.

Operational Expansion and Market Reach​

The robust financial results were underpinned by strategic operational advancements and expanding market engagement. OneSource is advancing its capacity expansion plan, with a second cartridge line set to commercialize in Q2. This development signifies continued progress toward scaling operations.

In addition to these internal milestones, the company has expanded its customer base and deepened its specialized capabilities:

• Commercial Momentum: The company is actively expanding engagement across modalities, supported by a growing opportunity pipeline.
• Biosimilars Focus: Two marquee biosimilar partnerships have been announced, strengthening the pipeline visibility for the biologics division.
• DDC Capabilities: One of the company's key differentiators is its status as a first and only CDMO with three G7 semaglutide approvals.
• International Footprint: The company has secured contracts in multiple regions, including supplying partners across key off-patent semaglutide markets in North America (CANADA) and the Middle East and North Africa (MENA).

FY28 Outlook Reaffirmed​

OneSource Specialty Pharma Limited reaffirmed its financial outlook for Fiscal Year 2028. The company projected $400 million in organic revenue, supported by maintaining a steady state EBITDA margin of 40%. This continued focus on growth is driven by strategic pillars including scaling DDCs (Drug Device Combinations), expanding the biologics funnel, and strengthening the base business through sterile injectable and softgel platforms.

ONESOURCE Stock Price Movement​

Shares of Onesource Specialty Pharma Limited on Friday slipped by 0.32% to settle at ₹1653.90 per share. Trading activity saw a total volume of 87,251 shares throughout the session.